References
- Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. Herz 2010;35:240–243.
- Medeiros K, O'Connor MJ, Baicu CF, Fitzgibbons TP, Shaw P, Tighe DA, et al. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation 2014;129:1659–1667.
- Komamura K, Fukui M, Iwasaku T, et al. Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment. World J Cardiol 2014;6:602–609.
- Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929–938.
- Garcia M, Mulvagh SL, Bairey Merz CN, et al. Cardiovascular disease in women: clinical perspectives. Circ Res 2016;118:1273–1293.
- Manfredini R, Fabbian F, De Giorgi A, et al. Heart and lung, a dangerous liaison-Tako-tsubo cardiomyopathy and respiratory diseases: a systematic review. World J Cardiol 2014;6:338–344.
- Saito N, Suzuki M, Ishii S, et al. Asthmatic attack complicated with Takotsubo cardiomyopathy after frequent inhalation of inhaled corticosteroids/long-acting beta2-adrenoceptor agonists. Intern Med 2016;55:1615–1620.
- Pontillo D, Patruno N, Stefanoni R. The tako-tsubo syndrome and bronchial asthma: the chicken or the egg dilemma. J Cardiovasc Med (Hagerstown) 2011;12:149–150.
- Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl J Med 2005;352:539–548.
- Lyon AR, Rees PS, Prasad S, et al. Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008;5:22–29.
- Ueyama T, Ann N Y. emotional stress-induced Tako-tsubo cardiomyopathy: animal model and molecular mechanism. Acad Sci 2004;1018:437.
- Nef HM, Möllmann H, Kostin S, Troidl C, Voss S, Weber M, et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J 2007;28:2456.
- Gianni M, Dentali F, Grandi AM, et al. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 2006;27:1523.
- Lyon AR, Rees PS, Prasad S, et al. Stress (Takotsubo) cardiomyopathy – a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008;5:22.
- Yoshikawa T. Takotsubo cardiomyopathy, a new concept of cardiomyopathy: clinical features and pathophysiology. Int J Cardiol 2015;182:297–303.
- Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O'Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in aβ2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Hard Circul 2012;126:697–706.
- Karch SB, Billingham ME. Myocardial contraction bands revisited. Hum Pathol 1986;17:9.
- Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, Pomara C, et al. Myocardial disarray: an architectural disorganization linked with adrenergic stress. Int J Cardiol 2005;99:277.
- Osuorji I, Williams C, Hessney J, et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009;102:301–303.
- Abraham J, Mudd JO, Kapur NK, et al. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009;53:1320–1325.
- Donohue D, Movahed MR. Clinical characteristics, demographics and prognosis of transient left ventricular apical ballooning syndrome. Heart Fail Rev 2005;10:311–316.
- Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: a systematic review. Int J Cardiol 2008;124:283–292.
- Vidi V, Rajesh V, Singh PP, Mukherjee JT, Lago RM, Venesy DM, et al. Clinical characteristics of takotsubo cardiomyopathy. Am J Cardiol 2009;104:578–582.
- Potu KC, Raizada A, Gedela M, Stys A. Takotsubo cardiomyopathy (broken-heart syndrome): a short review. S D Med 2016;69:169–171.
- Yamakage M, Iwasaki S, Jeong SW, Satoh J, Namiki A. Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung 2009;38:48–55.
- Tafreshi MJ, Weinacker AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999;19:974–978.
- Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, et al. Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol 1986;26:169–174.